<DOC>
	<DOCNO>NCT00712959</DOCNO>
	<brief_summary>The purpose study collect additional immunogenicity safety data re-dosing Tdap vaccine ( ADACEL® ) continue effort address public health need establish broad population immunity pertussis , well diphtheria tetanus . Primary Objective : - To assess immune response Tdap vaccine ( ADACEL® ) one month booster vaccination .</brief_summary>
	<brief_title>Immune Responses Adults Revaccination With ADACEL® 10 Years After Previous Dose</brief_title>
	<detailed_description>This open-label , multicenter study describe immunological response safety repeat administration adolescent/adult-formulation tetanus-diphtheria-acellular pertussis Tdap vaccine ( ADACEL® ) , 10 year follow initial administration Tdap vaccine .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Received Tdap TdapIPV vaccine study TD9707 TD9805 . Never previously receive Tdap vaccine receive tetanus , diphtheria , pertussiscontaining vaccine past 10 year . Participated TD9707 TD9805 meet inclusion/ exclusion criterion willing undergo phlebotomy willing receive Tdap ( ADACEL® ) vaccine . Signed Institutional Review Board ( IRB ) approve informed consent form Able attend schedule visit comply trial procedure For woman , negative urine pregnancy test use effective method ( ) contraception , inability become pregnant Exclusion Criteria : Any condition list contraindication ADACEL® Canadian product monograph Any condition , opinion investigator , would pose health risk subject interfere evaluation vaccine Chronic illness , stage could interfere trial conduct completion , opinion investigator Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic ( injected oral ) corticosteroid therapy . Individuals taper dose schedule oral steroid last less 7 day may include trial long receive 1 course within last 2 week prior enrollment Febrile illness ( temperature ≥ 37.5°C [ 99.5°F ] ) time inclusion History document diphtheria , pertussis , tetanus disease since participation study TD9707 TD9805 . Or history document diphtheria , pertussis , tetanus disease last 10 year . Known suspected receipt diphtheria , pertussis , tetanuscontaining vaccine since participation study TD9707 TD9805 . For Group 2 , know suspected receipt diphtheria , pertussis , tetanuscontaining vaccine last 10 year . Receipt vaccine , influenza vaccine , 28day period prior Visit 1 schedule receive vaccine , influenza vaccine , period Visit 1 Visit 2 . For influenza vaccine , defer receive 14 day prior enrollment schedule receive prior Visit 2 . Receipt blood bloodderived product past 3 month Suspected known hypersensitivity vaccine component , lifethreatening reaction previous administration vaccine vaccine contain substance Unable attend schedule visit comply study procedure In female childbearing potential , known pregnancy positive serum/urine pregnancy test Breastfeeding woman Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede enrollment . Planned participation another clinical trial present trial period Current alcohol recreational drug use may interfere subject 's ability comply trial procedure Thrombocytopenia , bleed disorder , anticoagulation therapy contraindicate intramuscular ( IM ) vaccination Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent . Other event judgment investigator would preclude vaccination time Visit 1 For Group 3 History document diphtheria , pertussis , tetanus disease since participation study TD9707 TD9805 Known suspect receipt diphtheria , pertussis , tetanuscontaining vaccine since participation study TD9707 TD9805 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Pertussis</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Acellular pertussis</keyword>
	<keyword>ADACEL® ,</keyword>
	<keyword>Tdap vaccine</keyword>
</DOC>